Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Subcutaneous panniculitis-like T-cell lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1

Interventions

Vincristine 4Prednisone 3MLN 8237 3Doxorubicin 3Cyclophosphamide 3temsirolimus 2romidepsin 2Specimen Handling 2Sirolimus 2Rituximab 2Lenalidomide 2Lactones 2Etoposide 2Depsipeptides 2Biopsy 2veliparib 1tipifarnib 1tazemetostat 1talimogene laherparepvec 1siplizumab 1pegaspargase 1molibresib 1merphos 1liposomal doxorubicin 1entinostat 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1avelumab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell × siplizumab × Clear all
NCT01445535 2021-11-03

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 18 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡